Home | Welcome to Contract Pharma   
Last Updated Thursday, December 18 2014

Print RSS Feed

Search Results for 'Financial Report: AMRI 3Q'

Search For:
Refine by Dates:
From: To:
Past 7 Days        Past 30 Days
Refine By Content:

Search Results:

Published November 7, 2014
Contract revenue up 8% in the quarter Read More »
Published October 28, 2014
Restructuring to decrease facilities footprint by 23% and a 20% reduction in staff by the end of 2015 Read More »
Published October 28, 2014
Generic competition, termination of Enbrel, Spiriva alliances impact results Read More »
Published October 28, 2014
Revenue up 4% in the quarter Read More »
Published October 14, 2014
Pharmaceutical sales up 18% in the quarter, new products drive growth Read More »
Published November 6, 2013
Contract revenue up 16% in the quarter Read More »
Published November 6, 2012
Large-scale manufacturing revenue up 14% Read More »
Published November 8, 2011
Achieves 17% growth in large-scale manufacturing, exits internal pharma R&D Read More »
Published November 7, 2008
AMRI 3Q Revenues: $61.4 million (+29%) 3Q Earnings: $7.0 million (+250%) YTD Revenues: $172.9 million (+19%) YTD Earnings: $17.4 million (+78%) Comments: Total contract revenue for the quarter was $54.1 million (+30%). Discovery Servi… Read More »
By Anna Shagako, Clinical Operations Head

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On